K562 AZQR Cell Line
Invented at Cancer Research UK Manchester Institute
- Datasheet
- References (2)
- Inventor Info
Info
| Catalogue Number | 153252 |
| Parental Line | K562 |
| Host | Human |
| Tissue | Lymphatic Tissue |
| Disease Keywords | Human caucasian chronic myelogenous leukemia (drug resistant) |
| Model | Tumour line |
| Relevance | The cells have been shown to contain decreased levels of glutathione and superoxoid dismutase. They are cross-resistant to adriamycin, mitzolamide, MMNG and mitmycin. Cells should be challenged with AZQ at every 4th passage at a minimum density of 100,000 cells/ml. It is recommended to cultivate the cells without drug on resuscitation. |
| Production Details | The drug resistant cell line K562 AZQ was developed from the parent K562 cell line by treatment with AZQ C215-bis (carboethoxyamino)-3, 6-diazitinyl 1;4 (benzoquinone). |
| Conditional | No |
| Research Area | Cancer, Drug Discovery & Development |
| Growth/Phenotype Keywords | Suspension |
| Recommended Growing Conditions | Subculture Routine: Maintain cultures between 3-9 x 100,000 cells/ml; 5% CO2; 37°C.Culture Medium: RPMI 1640 + 10% Foetal Bovine Serum (FBS) + 2mM Glutamine. Challenge with 1 mM AZQ every 4th passage. |
| Cellosaurus ID | CVCL_2967 |
References: 2 entries
Ward et al. 1995. Biochem Pharmacol. 50(4):459-64. PMID: 7646550.
Cross-resistance studies on two K562 sublines resistant to diaziridinylbenzoquinones.
Europe PMC ID: 7646550
Add a reference
References: 2 entries
Ward et al. 1995. Biochem Pharmacol. 50(4):459-64. PMID: 7646550.
Cross-resistance studies on two K562 sublines resistant to diaziridinylbenzoquinones.
Add a reference
